Patents Examined by Gregory Hook
  • Patent number: 5420162
    Abstract: The present invention relates to a method of inhibiting the protein kinase C-mediated biological response inflammation. The method comprises administering to a mammal a non-tumor promoting 12-deoxyphorbol ester. Phorbol esters suitable for use in the method include 12-deoxyphorbol 13-monoesters wherein the ester is a formate, acetate, propionate, butyrate, pentanoate, hexanote, benzoate or phenylacetate ester. The invention also relates to novel 12-deoxyphorbol 13-monoesters, wherein the ester can be a formate, propionate, butyrate or pentanoate ester, and to pharmaceutical compositions comprising same.
    Type: Grant
    Filed: July 31, 1992
    Date of Patent: May 30, 1995
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Peter M. Blumberg, Zoltan Szallasi
  • Patent number: 5389621
    Abstract: A method of enhancing the anticoagulant effect of aspirin is disclosed, wherein salicylamide is coadministered. Salicylamide is essentially without anticoagulant effects of its own. A normal dose of salicylamide, approximately 30 mg to about 3.0 grams administered daily, or about 3 to 9 mg/kg body weight, can increase the anticoagulant effect of aspirin. This is particularly desirable in patients who are undergoing long-term anticoagulant therapy, e.g., cardiac patients.
    Type: Grant
    Filed: February 18, 1994
    Date of Patent: February 14, 1995
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Mohamed S. Abdel-Rahman, Maged M. Rizk
  • Patent number: 5374660
    Abstract: Disclosed is a method of inhibiting fibrosis in a human or animal subject afflicted with a fibrosing disorder. The method comprises administering to the subject an effective fibrosis-inhibiting amount of a compound of Formula (I): ##STR1## wherein: n is 1 or 2;R is selected from the group consisting of hydrogen, C1-C4 alkyl, hydroxy, amino, and nitro; andR' is selected from the group consisting of hydrogen and C1-C4 alkyl.or a pharmaceutically acceptable salt thereof. Preferred as a compound of Formula (I) is benzoic hydrazide. Pharmaceutical formulations and the use of compounds of Formula (I) for making the same are also disclosed.
    Type: Grant
    Filed: February 16, 1993
    Date of Patent: December 20, 1994
    Assignee: Duke University
    Inventors: Saood Murad, Sheldon R. Pinnell
  • Patent number: 5371089
    Abstract: Compositions and methods are provided for countering the adverse effects of aging on cells in culture and in vivo in which cells are contacted with the compositions that ameliorate the adverse effects of aging on mammalian cells by slowing or reversing the changes that normally accompanying aging of such cells but do not significantly increase the growth rate or total proliferative capacity of such cells. The compositions contain one or more 6-(substituted amino)purine cytokinins and preferably do not contain ingredients that promote cell division or that induce or potentiate the ability of the 6-(substituted amino) purine cytokinins to promote cell division.Among the preferred applications of the compositions and methods provided herein are the preservation of or restoration of the health of mammalian cells in culture and, by application of the compositions to human skin, the health and youthful appearance of the skin.
    Type: Grant
    Filed: March 4, 1994
    Date of Patent: December 6, 1994
    Assignee: Senetek, PLC
    Inventor: Suresh I. S. Rattan
  • Patent number: 5369111
    Abstract: Sensitizing tumoral cells to anticancerous drugs and/or inhibiting the tumoral cells resistance to antitumoral drugs employing as a modulator agent a vinca alkaloid dimer, analog to vinblastine or vincristine, with a low cytotoxicity or devoid of cytotoxicity, comprising at least one stereoisomerism different from that of vinblastine or vincristine in the C-14', C-16' or C-20' position. Notably, the modulator agent may have the R absolute configuration in the C-16' position.
    Type: Grant
    Filed: June 19, 1992
    Date of Patent: November 29, 1994
    Assignee: University of Vermont
    Inventors: Martin E. Kuehne, Linda S. Borman
  • Patent number: 5366967
    Abstract: The antireactive-antiasthmatic effect of inhaled loop diuretics is potentiated by the use of a combination of a loop diuretic and a non-steroidal anti-inflammatory drug as an inhalant for combating asthma. The use of a cyclooxygenase inhibitor as the non-steroidal anti-inflammatory drug is preferred, particularly preferred is the use of furosemide as the loop diuretic. Especially advantageous is the use of piretanide as the loop diuretic. Particularly preferred is the use of acetylsalicylic acid as the non-steroidal anti-inflammatory drug.The most remarkable finding of this invention is the excellent and steady protective effect afforded by the combination of the two drugs in the patients with late asthmatic reactions between the seventh and eighth hour, when the effect of treatment with either drug alone appeared to be progressively decreasing.
    Type: Grant
    Filed: May 21, 1993
    Date of Patent: November 22, 1994
    Assignee: Hoechst Aktiengesellschaft
    Inventor: Sebastiano Bianco
  • Patent number: 5366977
    Abstract: A method of treating cells having a reduced apical Cl.sup.- conductance, such as that characteristic of cystic fibrosis cells, by contacting cells having a reduced apical Cl.sup.- conductance with a therapeutically effective quantity of a compound that antagonizes the A.sub.1 -adenosine cell receptor and does not antagonize the A.sub.2 -adenosine cell receptor. Suitable compounds include 8-cyclopentyl-1,3-dipropylxanthine (CPX), xanthine amino congener (XAC), and therapeutically effective derivatives thereof.
    Type: Grant
    Filed: September 29, 1992
    Date of Patent: November 22, 1994
    Assignee: The United States of America, as represented by the Department of Health and Human Services
    Inventors: Harvey B. Pollard, Philip J. M. van Galen, Kenneth A. Jacobson
  • Patent number: 5366979
    Abstract: Analgesic compositions containing stereoisomerically pure normorphine and norcodeine derivatives or pharmaceutically acceptable acid addition salts thereof are described. Methods of administering the novel compositions to achieve analgesia are described as well.
    Type: Grant
    Filed: June 7, 1990
    Date of Patent: November 22, 1994
    Assignee: Pharmaco Development Partners
    Inventor: John A. Lawson
  • Patent number: 5354774
    Abstract: A method for inhibiting smooth muscle cell proliferation in an injured blood vessel includes the steps of administering a photoactivatable psoralen to a patient in an amount to achieve local arterial tissue levels of psoralen suitable for light-dependent inhibition of smooth muscle cell growth, and delivering radiation in the visible wavelength range to the injured region of the blood vessel at a level sufficient for photoactivation of the psoralen. The psoralen is preferably 8-methoxypsoralen and can be delivered systemically or locally. The method of the invention can be used for preventing restenosis in a blood vessel following transluminal angioplasty. Both the psoralen and the visible light can be delivered with a laser balloon catheter having a porous balloon. The method of the invention may also be used for inhibiting proliferation of other undesired cell types in a patient's body.
    Type: Grant
    Filed: December 24, 1992
    Date of Patent: October 11, 1994
    Assignee: Yale University
    Inventors: Lawrence I. Deckelbaum, Francis P. Gasparro, Bauer K. Sumpio
  • Patent number: 5354771
    Abstract: Methods for treatment of free-radical-mediated tissue injury, particularly sepsis, are provided wherein compositions containing at least one keto analog of a branched-chain amino acid are administered. The composition is administered orally or parenterally, preferably in frequent or continuous dosages. Preferred forms of the keto analogs are their ornithine, arginine, or sodium salts.
    Type: Grant
    Filed: June 24, 1993
    Date of Patent: October 11, 1994
    Assignee: The Johns Hopkins University
    Inventor: MacKenzie Walser
  • Patent number: 5352440
    Abstract: A method for inducing melanin synthesis in melanocytes, thereby increasing the melanin content of melanocytes and, thus, increasing pigmentation, melanocytes with increased melanin content produced by these methods, and uses thereof.
    Type: Grant
    Filed: August 21, 1992
    Date of Patent: October 4, 1994
    Assignee: Trustees of Boston University
    Inventors: Barbara A. Gilchrest, Philip R. Gordon
  • Patent number: 5352691
    Abstract: A treatment modality for infectious diseases and pulmonary conditions that result from the inflammatory responses by tissues to infections by microorganisms, including but not limited to viruses, retroviruses, bacteria, or other microorganisms, or toxins that arise from microorganisms comprises administering an effective amount of histidine to the affected subject to combat the disease or the distress condition resulting therefrom.
    Type: Grant
    Filed: February 16, 1993
    Date of Patent: October 4, 1994
    Inventor: Peter G. Thomas
  • Patent number: 5352676
    Abstract: This invention relates to a method of treating rheumatoid arthritis, which method comprises administering to a mammal a therapeutically effective amount of a compound of formula (I): ##STR1## wherein R1 is unsubstituted or substituted phenyl;R.sub.2 is a morpholinomethyl group;R.sub.3 is hydrogen;R.sub.4 is hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.a is hydrogen; andR.sub.b is a group --(A).sub.m --R.sub.5 wherein m is zero or 1, A is a C.sub.1 -C.sub.6 alkylene chain and R.sub.5 is unsubstituted or substituted phenyl;or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 1, 1993
    Date of Patent: October 4, 1994
    Assignee: Farmitalia Carlo Erba Srl
    Inventors: Gianfederico Doria, Anna M. Isetta, Rinaldo Ferreccio, Mario Ferrari, Maria C. Fornasiero, Domenico Trizio
  • Patent number: 5352688
    Abstract: Neuropsychiatric symptoms of Parkinson's Disease and particularly the symptoms of apathy-amotivation and mental slowing can be ameliorated by treating a patient suffering from Parkinson's Disease with a histamine H.sub.2 -antagonist that passes the blood brain barrier. Suitable H.sub.2 -antagonists include famotidine and ranitidine. The H.sub.2 -antagonists may be co-administered with other compounds such as histamine H,-antagonists which are known to be useful in the treatment of Parkinson's Disease, and can be formulated with such other compounds into a therapeutic composition.
    Type: Grant
    Filed: September 30, 1992
    Date of Patent: October 4, 1994
    Assignee: The Mount Sinai School of Medicine of the City University of New York
    Inventor: Ram Kaminski
  • Patent number: 5346886
    Abstract: The invention provides a pharmaceutical composition for the treatment of a mammal having a skin disease. The composition contains a serine protease inhibitor and an effective amount of a cationic quaternary ammonium salt at a concentration below the critical micelle concentration for increasing the penetration of the inhibitor in the skin. Additionally, these may be included an ethoxylated nonylphenol.
    Type: Grant
    Filed: November 15, 1993
    Date of Patent: September 13, 1994
    Inventors: John Lezdey, Allan Wachter
  • Patent number: 5342832
    Abstract: A method of preventing or alleviating tissue damage, diabetes and complications thereof, bone disorders, disorders related to transplantation, disorders related to abnormal levels of lipoproteins, cardiovascular disease and inflammatory disorders by providing a mammal having one or more of the above diseases with a preventing or an alleviating effective amount of a compound having the formula C.sub.6 H.sub.6 (OH).sub.6-n (OPO.sub.3 H.sub.2).sub.n, where n is an integer of 1 or 2.
    Type: Grant
    Filed: August 21, 1992
    Date of Patent: August 30, 1994
    Assignee: Perstorp AB
    Inventor: Matti Siren
  • Patent number: 5336669
    Abstract: A parmaceutical preparation consisting essentially of a lyophilized cake of cyclophosphamide monohydrate and lactose prepared by the process of freezing cyclophosphamide, lactose and water, lyophilizing part of the water, obtaining and melting a supersaturated cyclophosphamide-lactose solution, precipitating cyclophosphamide as a hydrated polymorph, refreezing the solution and lyophilizing the water not bound to cyclophosphamide or lactose.
    Type: Grant
    Filed: May 20, 1993
    Date of Patent: August 9, 1994
    Assignee: Erbamont, Inc.
    Inventors: Nageswara R. Palepu, Tomaz R. Herzyk
  • Patent number: 5336485
    Abstract: Ionizable congeners of aromatic and aliphatic alcohols provide potent cytoprotective properties in vivo and in vitro. Alpha-tocopherol succinate, cholesteryl succinate, cholesteryl sulfate, dihydrocholesterol succinate, dihydrocholesterol sulfate, and ergosterol analogs are particularly good cytoprotective agents. In addition, the tris salts of these compounds have superior cytoprotective properties.
    Type: Grant
    Filed: March 10, 1993
    Date of Patent: August 9, 1994
    Assignees: Center for Innovative Technology, Virginia Commonwealth University
    Inventor: Marc W. Fariss
  • Patent number: 5334615
    Abstract: A composition embraces an oil, for instance, a mineral oil, animal oil, or plant or vegetable oil, in combination with an acetal that can release aldehyde functionality on aqueous contact. It may be used in a method for kill or control of bacterium or virus for a suitable part of a human being or animal subject. For example, a 5% mineral oil and 2,2'-trimethylenebis(1,3-dioxolane) mixture can be used as a microbiocidal lubricant for drill bits in dentistry, or a suitably formulated composition may be used topically.
    Type: Grant
    Filed: December 17, 1992
    Date of Patent: August 2, 1994
    Inventor: Wilhelm E. Walles
  • Patent number: 5332567
    Abstract: A method of targeting a diagnostic or therapeutic agent to a focus of infection comprises injecting a patient infected with a pathogen parenterally with an antibody conjugate which specifically binds to an accessible epitope of the pathogen or of a pathogen-associated antigen accreted at the focus of infection, the antibody conjugate further comprising a bound diagnostic or therapeutic agent for detecting, imaging or treating the infection. Polyspecific composite conjugates enhance the efficacy of the method, which is especially useful for treating infections that are refractory towards systemic chemotherapy.
    Type: Grant
    Filed: March 22, 1993
    Date of Patent: July 26, 1994
    Assignee: Immunomedics
    Inventor: M. David Goldenberg